Published in Cancer on June 15, 2003
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet (2006) 8.32
Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis (2002) 5.34
A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell (2012) 4.49
A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe (2009) 4.24
Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
Hepatic portal venous gas: the ABCs of management. Arch Surg (2009) 3.76
Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest (2003) 3.40
NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw (2009) 3.25
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Hepatocellular carcinoma: the need for progress. J Clin Oncol (2005) 3.11
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist (2011) 3.05
High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology (2004) 2.91
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg (2015) 2.79
CD8 epitope escape and reversion in acute HCV infection. J Exp Med (2004) 2.77
Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res (2008) 2.71
Case records of the Massachusetts General Hospital. Case 23-2005. A 57-year-old man with a mass in the liver. N Engl J Med (2005) 2.67
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology (2008) 2.45
The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int (2009) 2.33
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol (2007) 2.33
Development of an accurate index for predicting outcomes of patients with acute liver failure. Gastroenterology (2012) 2.26
Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer (2009) 2.19
Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology (2009) 2.13
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol (2011) 2.13
Viral sequence evolution in acute hepatitis C virus infection. J Virol (2007) 2.13
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13
A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology (2011) 2.08
Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol (2002) 2.03
Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood (2008) 2.01
High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome. J Virol (2007) 2.01
Systemic therapy for biliary tract cancers. Oncologist (2008) 1.98
Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol (2002) 1.98
Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA (2008) 1.94
Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J Virol (2006) 1.87
Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience. Radiology (2007) 1.87
Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. Gastroenterology (2005) 1.87
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol (2006) 1.86
Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res (2012) 1.83
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
Coinfection with HIV-1 and HCV--a one-two punch. Gastroenterology (2009) 1.78
FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist (2013) 1.76
Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl (2005) 1.76
Non-high-density lipoprotein cholesterol as a biomarker for nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2012) 1.74
Influence of high body mass index on outcome in acute liver failure. Clin Gastroenterol Hepatol (2006) 1.74
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology (2006) 1.73
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res (2010) 1.71
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71
Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol (2010) 1.69
Spontaneous resolution of chronic hepatitis C virus disease after withdrawal of immunosuppression. Gastroenterology (2003) 1.68
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol (2006) 1.64
A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol (2008) 1.64
IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol (2010) 1.64
GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype. J Infect Dis (2006) 1.64
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology (2009) 1.63
HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology (2008) 1.60
Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol (2005) 1.59
Gc-globulin and prognosis in acute liver failure. Liver Transpl (2005) 1.59
Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol (2005) 1.54
The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood (2004) 1.53
Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol (2002) 1.52
Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology (2010) 1.51
Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology (2010) 1.51
Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance. Liver Transpl (2008) 1.50
Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis (2009) 1.49
Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology (2010) 1.48
Management strategies using pharmacogenomics in patients with severe HCV-1b infection: a decision analysis. Hepatology (2002) 1.47
Kinetic differences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virus. Hepatology (2014) 1.46
Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution. Hepatology (2007) 1.44
Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology (2005) 1.44
Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med (2012) 1.43
A functional genomic screen reveals novel host genes that mediate interferon-alpha's effects against hepatitis C virus. J Hepatol (2011) 1.41
A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. Gastroenterology (2006) 1.40
Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol (2002) 1.40
Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res (2013) 1.39
Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med (2006) 1.36
Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in Hepatitis C virus infection outcome. Mol Immunol (2008) 1.36
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer (2011) 1.36
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res (2014) 1.33
Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol (2012) 1.33
Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer. Ann Surg (2005) 1.30
Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer (2007) 1.30
Serum apoptosis markers in acute liver failure: a pilot study. Clin Gastroenterol Hepatol (2007) 1.29
Intrahepatic cholangiocarcinoma. Surg Clin North Am (2010) 1.27
Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology (2005) 1.26
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther (2009) 1.26
Gemcitabine-associated thrombotic microangiopathy. Cancer (2004) 1.26
HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB. J Biol Chem (2010) 1.24
Anti-hepatitis C virus drugs in development. Gastroenterology (2012) 1.23
Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int (2010) 1.22
Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol (2011) 1.22
Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation (2004) 1.22
Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer (2011) 1.20
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology (2009) 1.18
Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol (2004) 1.18